Human Milk Oligosaccharides
Investor Brief
A 28-page sector note on Human Milk Oligosaccharides at the inflection point: a Chinese cost cohort now at near-parity with Western mature plants, the manufacturing-IP staircase running 2027 to 2035, and value migrating off the flagship 2'-FL into multi-HMO blends. Written from inside the industry, with a named, dated, falsifiable forward call on where the durable Western returns live..